Serum uric acid level is associated with cardiac hypertrophy in renal transplant recipients

Clinical Transplantation

Volumn 25, Issue 3, 2011, Pages 368-374

  Caliskan, Yasar ^a   Gorgulu, Numan ^a   Yelken, Berna ^a   Akturk, Faruk ^b   Yazici, Halil ^a   Turkmen, Aydin ^a   Sever, Mehmet Sukru ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Left ventricle mass index; Left ventricular hypertrophy; Renal transplantation; Uric acid

Indexed keywords

URIC ACID;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; DEMOGRAPHY; DIALYSIS; FEMALE; GRAFT RECIPIENT; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY GRAFT; LIVER FUNCTION TEST; LUNG ARTERY PRESSURE; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; CARDIOMEGALY; CREATININE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERURICEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; URIC ACID; YOUNG ADULT;

EID: 79958756130     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01244.x     Document Type: Article

References (27)

1. Stewart G, Jardine AG, Briggs JD. Ischemic heart disease following renal transplantation. Nephrol Dial Transplant 2000: 15: 269.
2. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003: 22: 1991.
3. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000: 11: 974.
4. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporin induced hyperuricemia and gout. N Engl J Med 1989: 321: 287.
5. Edvardsson VO, Kaiser BA, Polinsky MS, Palmer JA, Quien R, Baluarte HJ. Natural history of hyperuricemia following paediatric renal transplantation. Pediatr Nephrol 1995: 9: 57.
6. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006: 47: 195.
7. Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005: 67: 1739.
8. Viazzi F, Parodi D, Leoncini G et al. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005: 45: 991.
9. Casale PN, Devereux RB, Milner M et al. Value of echocardiographic measurement left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986: 105: 173.
10. Aronow WS. Left ventricular hypertrophy. Significance in cardiac morbidity and mortality. Postgrad Med 1990: 87: 147.
11. Schiller NB, Shah PM, Crawford M et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989: 2: 358.
12. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977: 55: 613.
13. Wang Y, Moss J, Thisted R. Predictors of body surface area. J Clin Anesth 1992: 4: 4.
14. Hammond IW, Devereux RB, Alderman MH et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986: 7: 639.
15. Lee JA, Kim DH, Yoo SJ, Oh DJ, Yu SH, Kang ET. Association between serum N-terminal pro-brain natriuretic peptide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2006: 26: 360.
16. Costello-Boerrigter LC, Boerrigter G, Redfield MM et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006: 47: 345.
17. Wang AY, Lam CW, Yu C et al. Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. Kidney Int 2006: 70: 444.
18. Marcen R, Gallego N, Orofino L et al. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 1995: 70: 307.
19. Ochiai T, Ishibashi M, Fukao K et al. Japanese multicenter studies of FK 506 in renal transplantation. Transplant Proc 1995: 27: 50.
20. Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation 2005: 80: 1383.
21. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003: 41: 1183.
22. Bonora E, Targher G, Zenere MB et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. The role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord 1996: 20: 975.
23. Zavaroni I, Mazza S, Fantuzzi M et al. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricemia. J Intern Med 1993: 234: 25.
24. Doehner W, Schoene N, Rauchhaus M et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002: 105: 2619.
25. Leyva F, Anker SD, Swan JW et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997: 18: 858.
26. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991: 266: 8604.
27. Watanabe S, Kang DH, Feng L et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002: 40: 355.